Drug profile · INN
pivmecillinam hydrochloride
PIVYA
pivmecillinam hydrochloride (PIVYA) is a bacterial penicillin-binding protein 2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — pivmecillinam hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
pivmecillinam hydrochloride (PIVYA) is a bacterial penicillin-binding protein 2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial penicillin-binding protein 2 inhibitor
Primary target: Peptidoglycan D,D-transpeptidase MrdA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is pivmecillinam hydrochloride?
pivmecillinam hydrochloride (PIVYA) is a bacterial penicillin-binding protein 2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for pivmecillinam hydrochloride?
PIVYA is a marketed brand name for pivmecillinam hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pivmecillinam hydrochloride?
pivmecillinam hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.